Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neuroendocrine Tumor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD56/NCAM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD56/NCAM1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD56 Products |
| Gene Delivery | CD56/NCAM1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View CD56 Products |
| Benchmark Ab | Anti-CD56/NCAM1 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences (e.g., Lorvotuzumab). |
View CD56 Products |
| Validator | CD56/NCAM1 siRNA Set Target-specific knockdown pool for specificity and target validation assays. |
View CD56 Products |
| Related Target A | CD16a Fc-gamma receptor IIIa, crucial for evaluating NK-cell mediated ADCC in combination with CD56-targeting therapeutics. |
View CD16a Products |
| Related Target B | DLL3 Co-expressed neuroendocrine marker; highly relevant for bispecific targeting or combination therapies in Small Cell Lung Cancer (SCLC). |
View DLL3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus CD56 recombinant proteins available with >95% purity verified by SDS-PAGE. |
| Isoform-specific screening (120kDa vs 140kDa vs 180kDa) | Precisely mapped Extracellular Domain (ECD) constructs covering shared and unique immunogenic epitopes. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Sequence-verified siRNA included for target-specific knockdown validation. |
Live CD56/NCAM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD56/NCAM1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to next-generation antibody-drug conjugates (ADCs) and CAR-NK/CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific glycoforms and bispecific constructs to minimize systemic neurotoxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | ImmunoGen, Sanofi | Small Cell Lung Cancer (SCLC), Multiple Myeloma | Internalization Assay (Need high-purity ECD-Fc for binding and internalization kinetics) |
| CAR-NK / CAR-T | Academic Institutes, Biotech Startups | Neuroblastoma, Glioblastoma | Stable Cell Line Construction (Need Lentivirus Premade Particles for robust target expression) |
| Bispecific Antibodies (e.g., CD56 x CD3) | Oncology-focused Biotechs | Solid Tumors, Neuroendocrine Tumors | Dual-binding Affinity Validation (Need high-purity, monomeric human and cyno CD56 proteins) |